Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Psilocybin May Help Alleviate Cancer-Related Depressive Symptoms

January 9, 2025
By Michael P. Bogenschutz, MD
Commentary
Video

Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.

A need to provide effective medication to aid patients with psychological challenges related to a serious cancer diagnosis may be addressed by psilocybin, according to Michael P. Bogenschutz, MD.

CancerNetwork® spoke with Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine and professor of Psychiatry at NYU Grossman School of Medicine, about potential unmet needs that treatment with psilocybin-assisted psychotherapy (PAP) may reduce in the context of a pooled analysis of 2 phase 2 trials published in Nature Mental Health.

Bogenschutz began by highlighting a paucity of effective medicinal treatment to help patients manage psychological ailments associated with serious cancer diagnoses. He additionally detailed that although antidepressants can mitigate symptoms of depression, they have not been particularly effective in treating patients with cancer.

Describing the time after a serious cancer diagnosis as an adjustment period, Bogenschutz explained that PAP can treat those who would otherwise be incapacitated by psychological challenges. He further iterated that prior studies have shown how a single dose of psilocybin demonstrated lasting mitigative effects on depressive symptoms for weeks to months in patients with major depression. He concluded by expressing that patients under the influence of psilocybin may better come to terms with the reality of their cancer prognosis.

Efficacy findings from the pooled analysis study found that PAP was associated with improved anxiety (P = .0049), depression (P = .0007), interpersonal sensitivity (P = .0005), obsession-compulsion (P = .0002), hostility (P = .009), and somatization (P <.0001) among patients with cancer.

Transcript:

There are not any effective medications to help [patients with] psychological challenges presented by a serious cancer diagnosis. If [patients] have major depression, they can be treated with antidepressants. They can be treated with medicines for anxiety. The antidepressants do not appear to be particularly helpful in this population, and they do not address what the underlying cause is, which, in many cases, is [having] this existential crisis of one’s own possible or probable death in the near future.

In some ways, I tend to think about this situation as an adjustment reaction. [Patients have] a challenging situation, and they may become symptomatic [or] become incapacitated because of the psychological challenges. The psilocybin-assisted treatment, in some ways, acts like any other medication––to treat the symptoms. There are studies for major depression independent of a cancer diagnosis demonstrating enduring effects on depressive symptoms for weeks to months after a single dose of psilocybin.

In this population, one of the ideas behind how this works is that the experiences that [patients] have under the influence of psilocybin may help them better to come to terms with the reality of death and what that means, and to find some acceptance and meaning in the face of [a] challenging situation.

Reference

Petridis PD, Grinband J, Agin-Liebes G, et al. Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. Nat Mental Health. 2024;2:1408-1414. doi:10.1038/s44220-024-00331-0

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Related Content

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD
May 15th 2025
Article

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Preclinical data showing OBI-902 sustained antitumor activity in solid tumors support the agency’s decision for the IND application.

FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors

Roman Fabbricatore
May 2nd 2025
Article

Preclinical data showing OBI-902 sustained antitumor activity in solid tumors support the agency’s decision for the IND application.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Tim Cortese
April 28th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Related Content

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD
May 15th 2025
Article

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Preclinical data showing OBI-902 sustained antitumor activity in solid tumors support the agency’s decision for the IND application.

FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors

Roman Fabbricatore
May 2nd 2025
Article

Preclinical data showing OBI-902 sustained antitumor activity in solid tumors support the agency’s decision for the IND application.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Tim Cortese
April 28th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.